Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uprifosbuvir + Ruzasvir in Chronic HCV
NCT02759315Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of uprifosbuvir, ruzasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started May 2016; status: terminated.
02
Drugs
uprifosbuvirruzasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02759315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759315.